Get the Stockscreener App
0.6529
9.82%
0.0584
Context Therapeutics Inc stock is traded at $0.6529, with a volume of 3.89M.
It is up +9.82% in the last 24 hours and down -54.97% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.5945
Open:
$0.61
24h Volume:
3.89M
Relative Volume:
1.85
Market Cap:
$59.99M
Revenue:
-
Net Income/Loss:
$-40.23M
P/E Ratio:
-1.5273
EPS:
-0.4275
Net Cash Flow:
$-34.82M
1W Performance:
-0.12%
1M Performance:
-54.97%
6M Performance:
-59.45%
1Y Performance:
-2.57%
1-Day Range:
$0.5927
$0.671
1-Week Range:
$0.5601
$0.7021
52-Week Range:
$0.5451
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6529 | 59.99M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics (CNTX) Proxy filing Summary - Quartr
Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary - Quartr
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Context Therapeutics hire receives 146,000-share stock option at $0.70 - Stock Titan
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst - TipRanks
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes - marketscreener.com
Context Therapeutics Joins Russell 2000, Russell 3000 Indexes - Moomoo
Context Therapeutics stock rises on Russell index inclusion By Investing.com - Investing.com Nigeria
Context Therapeutics stock rises on Russell index inclusion - Investing.com
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Context Therapeutics joins Russell 2000 and 3000 indexes - Stock Titan
Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CNTX Stock Price, Quote & Chart - ChartMill
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Enterprise value to revenue forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Index - marketscreener.com
Context Therapeutics Shareholders Approve Stock Increase and Directors - The Globe and Mail
Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director Linda West awarded 45K stock options - Stock Titan
Director at Context Therapeutics (CNTX) receives 45,000 stock options award - Stock Titan
Director Philip Kantoff receives 45,000 CNTX stock options at $0.576 exercise price - Stock Titan
Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M - Stock Titan
Context Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Smith Karen L. - Moomoo
Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX) - TradingView
Price to sales forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Price to sales forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
CNTX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
Price to earnings forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Enterprise value to EBIT forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) Rallies 5% as Biotech Stock Tests Key ResistanceMFI Overbought - dars.gov.et
Context Therapeutics Inc (CNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Context Therapeutics Inc (CNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
CNTX Maintained by Maxim Group -- Price Target Lowered to $4.00 - GuruFocus
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):